Metrics as of 10/15/2026, 02:04 PM (Berlin time), refresh in progress.
Provexis Stock
Provexis plc
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United Kingdom
- CEO
- Ian Ford
- Employees
- 2
- Market cap
- £25 M
- IPO
- 28/06/2004
Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tomato extract designed to reduce the tendency for abnormal blood clot…
Provexis stock: price history
1D
+10.7%
1W
+10.7%
1M
-1.7%
6M
+2.1%
YTD
+16.9%
1Y
+70.4%
2Y
+76.1%
5Y
+25.2%
10Y
+116.9%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~42% weaker price swings than usual
Ask the agents about Provexis
Provexis stock metrics
P/E
-105.2
P/B
22.31
EV/EBITDA
-48.35
RETURN ON EQUITY
-17.4%
NET MARGIN
-21.4%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
77.2%
FLOAT SHARES
1,811,544,133
AVG. DAILY VOLUME (30D)
533,627
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Provexis stock
What does Provexis do?
Provexis plc is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United Kingdom.
The CEO is Ian Ford, the company employs around 2 people.
The IPO was on 28/06/2004; the stock trades on LSE under the ticker PXS.L.
When does Provexis report next?
Around past earnings, price swings were roughly -42% stronger than usual.
Does Provexis pay a dividend?
No, Provexis currently does not pay a dividend.
Which stocks are comparable to Provexis?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Provexis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Provexis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.